« Return to News | Clinical Intelligence

UCB, Amgen begin phase III postmenopausal osteoporosis program

Friday, April 6, 2012 03:47 PM

UCB, a global biopharmaceutical based in Brussels, Belgium, and biotech Amgen have initiated their sclerostin antibody (CDP7851/AMG785) phase III clinical trial program for the treatment of postmenopausal osteoporosis.

The international phase III program of CDP7851/AMG785 includes a multicenter, randomized, double-blind, placebo-controlled, parallel-group, two-year study in more than 5,000 postmenopausal women with osteoporosis.  The primary endpoint will evaluate the incidence of new vertebral fractures at 12 months. Initial results from the phase III program are expected by the end of 2015.

The study compound, CDP7851/AMG785, is a humanized monoclonal antibody that binds to and inhibits sclerostin, a protein secreted by bone cells that inhibits bone formation. By binding to and blocking sclerostin, CDP7851/AMG785 is designed to increase the amount of bone in the skeleton. With more than 75 million people worldwide suffering from osteoporosis, there is a serious patient need for therapeutics that help build bone.  Amgen and UCB hope to use the compound for the treatment of postmenopausal osteoporosis and fracture healing.

"Our sclerostin antibody project with Amgen is one of the most exciting pipeline programs in UCB's portfolio,” said Iris Loew-Friedrich, PhD, chief medical officer and executive vice president of global projects and development, UCB. “Data collected so far indicate the potential for a change of treatment paradigms in postmenopausal osteoporosis.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.